Post-earnings recap
Reported
Tue, Feb 24, 2026
EPS actual
$-1.04
EPS est.
$-0.17
EPS surprise
-522.75%
1-day move
+2.74%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report showed a significant EPS miss, but the stock reacted positively, rising by 2.74%. This increase may reflect investor optimism about the company's future prospects and ongoing projects, despite the disappointing earnings. The lack of revenue information and guidance leaves some uncertainty about the company's short-term performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.04 | N/A | -522.75% |
| Revenue | N/A | N/A | N/A |
Management remains focused on their long-term goals and is actively working on improving operational efficiencies. They acknowledged the challenges faced but emphasized their dedication to innovation.
Management highlighted ongoing efforts in drug development and patient engagement.
They expressed commitment to advancing their pipeline despite the EPS miss.